These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 33376301)

  • 1. Brexpiprazole for the Treatment of Schizophrenia in Adults: An Overview of Its Clinical Efficacy and Safety and a Psychiatrist's Perspective.
    Watanabe Y; Yamada S; Otsubo T; Kikuchi T
    Drug Des Devel Ther; 2020; 14():5559-5574. PubMed ID: 33376301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brexpiprazole: a new leaf on the partial dopamine agonist branch.
    Hope J; Castle D; Keks NA
    Australas Psychiatry; 2018 Feb; 26(1):92-94. PubMed ID: 29017334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Preclinical pharmacological profiles and clinical efficacy of the novel antipsychotic drug brexpiprazole (REXULTI
    Suzuki M; Niidome K; Maeda K; Kikuchi T; Usami T; Futamura T
    Nihon Yakurigaku Zasshi; 2019; 154(5):275-287. PubMed ID: 31735758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of brexpiprazole - a new antipsychotic drug from the group of dopamine D2 receptor partial agonists.
    Bieńkowski P; Wichniak A
    Psychiatr Pol; 2024 Apr; 58(2):237-248. PubMed ID: 39003508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia.
    Keks N; Hope J; Schwartz D; McLennan H; Copolov D; Meadows G
    CNS Drugs; 2020 May; 34(5):473-507. PubMed ID: 32246399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine D2 receptor partial agonists in the treatment of schizophrenia -example of brexpiprazole.
    Bliźniewska-Kowalska KM; Gałecki P
    Psychiatr Pol; 2024 Aug; 58(4):581-593. PubMed ID: 39378141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia.
    Kane JM; Skuban A; Hobart M; Ouyang J; Weiller E; Weiss C; Correll CU
    Schizophr Res; 2016 Jul; 174(1-3):93-98. PubMed ID: 27188270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brexpiprazole for the treatment of schizophrenia.
    Hsu WY; Lane HY; Lin CH
    Expert Opin Pharmacother; 2017 Feb; 18(2):217-223. PubMed ID: 27997809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2015 Sep; 69(9):978-97. PubMed ID: 26250067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brexpiprazole: a new dopamine D₂receptor partial agonist for the treatment of schizophrenia and major depressive disorder.
    Citrome L
    Drugs Today (Barc); 2015 Jul; 51(7):397-414. PubMed ID: 26261843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brexpiprazole for the treatment of schizophrenia.
    Yee A
    Expert Rev Neurother; 2016; 16(2):109-22. PubMed ID: 26650624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brexpiprazole has a low risk of dopamine D
    Amada N; Akazawa H; Ohgi Y; Maeda K; Sugino H; Kurahashi N; Kikuchi T; Futamura T
    Neuropsychopharmacol Rep; 2019 Dec; 39(4):279-288. PubMed ID: 31487433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brexpiprazole for the Treatment of Schizophrenia: A Review of this Novel Serotonin-Dopamine Activity Modulator.
    McEvoy J; Citrome L
    Clin Schizophr Relat Psychoses; 2016; 9(4):177-86. PubMed ID: 26757416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brexpiprazole: A Partial Dopamine Agonist for the Treatment of Schizophrenia.
    Ekinci A; Ekinci O
    Rev Recent Clin Trials; 2018 Jan; 13(1):37-44. PubMed ID: 28828976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of action of brexpiprazole: comparison with aripiprazole.
    Stahl SM
    CNS Spectr; 2016 Feb; 21(1):1-6. PubMed ID: 26899451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-hoc analysis investigating the safety and efficacy of brexpiprazole in Japanese patients with schizophrenia who were switched from other antipsychotics in a long-term study (Secondary Publication).
    Ishigooka J; Usami T; Iwashita S; Kojima Y; Matsuo S
    Neuropsychopharmacol Rep; 2020 Jun; 40(2):122-129. PubMed ID: 32297486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia.
    Forbes A; Hobart M; Ouyang J; Shi L; Pfister S; Hakala M
    Int J Neuropsychopharmacol; 2018 May; 21(5):433-441. PubMed ID: 29415258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brexpiprazole.
    Markovic M; Gallipani A; Patel KH; Maroney M
    Ann Pharmacother; 2017 Apr; 51(4):315-322. PubMed ID: 28228056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brexpiprazole for the Treatment of Schizophrenia and Major Depressive Disorder: A Comprehensive Review of Pharmacological Considerations in Clinical Practice.
    Edinoff AN; Wu NW; Maxey BS; Ren AL; Leethy KN; Girma B; Odisho A; Kaye JS; Kaye AJ; Kaye AM; Kaye AD; Mychaskiw G; Viswanath O; Urits I
    Psychopharmacol Bull; 2021 Mar; 51(2):69-95. PubMed ID: 34092824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two randomized, double-blind, placebo-controlled trials and one open-label, long-term trial of brexpiprazole for the acute treatment of bipolar mania.
    Vieta E; Sachs G; Chang D; Hellsten J; Brewer C; Peters-Strickland T; Hefting N
    J Psychopharmacol; 2021 Aug; 35(8):971-982. PubMed ID: 33691517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.